medRxivGenetic & Genomic MedicinePreprint
Unlocking the Treatment of FacioscapulohumeralMuscular Dystrophy Type 2: The Bisphenol Connection
Abstract
BackgroundFacioscapulohumeral muscular dystrophy type 2 (FSHD2) poses a significant challenge within the domain of neuromuscular disorders, marked by a progressive decline in muscle strength accompanied by tissue wasting. FSHD2 results from chromosomal deletions triggering the activation of a dormant gene known as DUX4. While DUX4 typically regulates early embryonic development, its activation in adult muscle cells leads to premature cell death. Despite this understanding, the exact pathology of FSHD2 remains unclear. To date, no effective treatment for FSHD2 exists. MethodWe acquired single-cell RNA sequencing (RNA-Seq) data (GSE143452) from primary myoblasts for FSHD2 from the United States National Institutes of Health (NIH) portal website. Our analysis encompassed a comprehensive examination of differentially expressed genes, alongside associated compounds sourced from the Chemical Entities of Biological Interest (ChEBI) database. Employing rigorous statistical methods, we pinpointed the most prominently upregulated and downregulated genes. Subsequently, we determined the compounds capable of modulating the expression of these top genes, either enhancing or reducing their activity. ResultsBisphenol S (BPS) can upregulate 52 of 100 top downregulated genes in FSHD2 without downregulating any other genes and Bisphenol F (BPF) can upregulate 45 of 100 downregulated genes with downregulating only one other gene. The enrichment analysis of both sets of 52 genes related to BPS and 45 genes corresponding to BPF highlights their significant involvement in various aspects of muscle biology, particularly as pertaining to the function and dysfunction of cardiac and skeletal muscle. ConclusionsLeveraging single-cell RNA-Seq data and computational analysis, we identified key dysregulated genes in FSHD2 and elucidated their modulation by compounds such as BPS and BPF. While effective treatments for FSHD2 remain elusive, our study provides valuable insights into potential therapeutic targets and pathways for further investigation in the pursuit of effective interventions for this debilitating condition. However, more research is needed to understand whether the roles of BPS and F are constructive or destructive.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Assessing Facioscapulohumeral Muscular Dystrophy through Comparative Analysis of Bulk and Single-Cell Transcriptomes
Saed Sayad, Mark Hiatt, Hazem Mustafa·medRxiv·Nov 23, 2023
- BAZ1A promotes expression of DUX4-fl and its lncRNA activator DBE-T in facioscapulohumeral muscular dystrophy
Ning Chang, Takako Iida Jones, … Charis L. Himeda·bioRxiv·Jun 19, 2026
- P38α Regulates Expression of DUX4 in Facioscapulohumeral Muscular Dystrophy
Luis Alejandro Rojas, Erin Valentine, … Owen B. Wallace·Journal of Pharmacology and Experimental TherapeuticsPeer-reviewed·Jun 23, 2020
- Lymphocytes contribute to DUX4 target genes in FSHD muscle biopsies
Christopher R. S. Banerji, Maryna Panamarova, Peter S. Zammit·Human Molecular GeneticsPeer-reviewed·Mar 31, 2020
- A circulating biomarker of facioscapulohumeral muscular dystrophy clinical severity, valid in skeletal muscle and blood
Christopher R. S. Banerji, Anna Greco, … Peter S. Zammit·bioRxiv·Aug 31, 2022
- Developmental regulators drive DUX4 expression in facioscapulohumeral muscular dystrophy
Amelia Fox, Jonathan Oliva, … Francis M. Sverdrup·bioRxiv·May 21, 2024